Ornithine decarboxylase (ODC), a rate-limiting enzyme of polyamine biosynthesis, has been shown to be required for entry into and progression through the cell cycle and to be a transcriptional target of the proto-oncogene, c-myc. We show that ODC transcripts and enzyme activity are downregulated following induction of myeloid differentiation, using M 1 myeloblastic leukemic cells and normal cells from bone marrow (BM), and fail to be suppressed when c-myc expression is deregulated. In Mlmycer cells, when endogenous c-myc expression has been suppressed following stimulation by interleukin-6 (IL-60). treatment with estrogen and cycloheximide results in induction of ODC transcripts. These data demonstrate that ODC is a c-myc target gene in M1 cells. It was of interest to determine whether deregulated EMATOPOIESIS is a profound example of cell homeostasis that is regulated throughout life, whereby a hierarchy of hematopoietic progenitor cells in the bone marrow (BM) proliferate and differentiate along multiple, distinct cell lineages, including the proliferation and differentiation of myeloid precursor cells into mature granulocytes and macrophages. Blocks in differentiation, a major step in tumor progression, can be caused by lesions in genes involved in the control of any one of the interrelated cellular processes comprising the developmental program of terminal differentiation."' The differentiation process is controlled by both positive and negative regulators, in which the negative regulators would be expected to be found among genes that control myeloid cell growth. The proto-oncogene, c-my, which fits this criterium, has been identified in our laboratory to be a negative regulator of terminal myeloid differentiat i~n .~. " c-myc has been shown to play a pivotal role in growth control, differentiation, and apoptosis, and its abnormal expression has been associated with many naturally occurring neoplasm^."'"^ c-myc is expressed in almost all proliferating normal cells, and is downregulated in many kinds of cells when they are induced to terminally differentiate.7."'.'2,'5 Forced expression of c-myc was shown to block differentiation in several cell types, including myeloid, erythroid, myogenic, preadipocyte, and nerve cell^.^^^^^"'^ The c-myc protein contains three structural domains that are homologous to domains found in characterized transcription factors, includ- ing a leucine zipper, a helix-loop-helix motif, and an adjacent domain rich in basic amino acids.'".'' It is localized to the nucleus, and its binding to DNA is sequence-specific." Recent experimental evidence suggests that c-myc functions as a transcriptional regulator as part of a network of interacting factors.'*,*' Given the central role c-myc plays in growth control, differentiation, and apoptosis, understanding how cm y functions will increase our understanding of normal cell development, and how alterations in these processes can lead to malignancy. Toward this end, it would be extremely useful to identify c -m y target genes and to assess their role(s) in the different biologic processes known to be regulated by c-
ODC expression would alter the myeloid differentiation program. To answer this question, M1-ODC cell lines constitutively expressing ODC were established. These cells can undergo terminal differentiation and growth arrest following IL-6 stimulation, exactly like parental M1 cells, demonstrating that deregulated ODC expression is not sufficient to block myeloid differentiation. Another question to be answered was whether ODC expression is necessary for the cmyc-mediated block in differentiation. The use of a-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC enzyme activity, indicates that ODC is not necessary for the c-myc-mediated differentiation block. 0 1996 by The American Society of Hematology.
ing a leucine zipper, a helix-loop-helix motif, and an adjacent domain rich in basic amino acids.'".'' It is localized to the nucleus, and its binding to DNA is sequence-specific." Recent experimental evidence suggests that c-myc functions as a transcriptional regulator as part of a network of interacting factors.'*,*' Given the central role c-myc plays in growth control, differentiation, and apoptosis, understanding how cm y functions will increase our understanding of normal cell development, and how alterations in these processes can lead to malignancy. Toward this end, it would be extremely useful to identify c -m y target genes and to assess their role(s) in the different biologic processes known to be regulated by c- Recently, evidence has accumulated via several strategies, including the use of the mycer transgene, to indicate that the ornithine decarboxylase (ODC) gene is a transcriptional target of c-myc.'4-26 ODC catalyzes the conversion of ornithine to putrescine, the first and rate-limiting step in polyamine biosynthesis, and has been shown to be crucial to cell growth. 27 Several lines of investigation have shown that ODC activity is critical for cell transformation.2X~3" It has also been shown that ODC expression is sufficient to induce accelerated apoptosis following interleukin-3 (IL-3) withdrawal in IL-3-dependent 32Dc13 myeloid cells, and is a mediator of c-myc-induced accelerated apoptosis in these cells." These data suggest that ODC mediates other c-myc functions in addition to transformation. With this in mind, several lines of experimentation were pursued to ascertain if deregulated ODC expression can negatively regulate myeloid differentiation, and if ODC is a mediator of the differentiation block due to deregulated c -m y expression. The availability of the myeloblastic leukemic MI cell line that can be induced for terminal differentiation and growth arrest by IL-6 or leukemia inhibitory factor,'.7 as well as normal myeloid cells that can be induced to undergo proliferation followed by differentiation and growth arrest, provided an opportunity to study the role of ODC in the myeloid differentiation program.
In this study, it was shown that ODC expression is downregulated following induction of myeloid differentiation and its associated growth arrest. Furthermore, when induction of differentiation is blocked by deregulated expression of Cm y , ODC continues to be expressed. Using the M1 cell line and M I variants established in our laboratory, it has been DNA probes. Plasmid preparations, restriction enzyme digestions, Viable cell numbers were determined by trypan blue dye exclusion DNA fragment Preparations, and agarose gel electrophoresis were and counting in a hemocytometer, M1myc-r transfectants were as described previously?" Probes for murine C -W Z~C and lysozyme maintained in phenol red-free DMEM-21 (GIBCO) containing 10%
Were the Same as used preViOUSly.7'8 The ODC probe was obtained dialyzed horse serum. M1 and Mlmyc2 cells were maintained in by excision from the PMV7-ODC vector.** DNA for probes was the same culture conditions when used as controls. PA317 (American Meled by random Priming, using the Rad Prime DNA-labeling Type Culture Collection, Rockville, MD), a viral packaging cell system (GIBCO-BRL), to a specific activity of at least 10' CPdPg line,3z was maintained in DMEM and 10% fetal bovine serum. Brief DNA. selection in HAT medium was periodically performed to select for RNA was cells retaining the packaging function. Myeloblast-enriched BM cells extracted using TRIZOL (GIBCO-BRL) reagent according to the were isolated from femurs of CD-1 mice (Charles River Laborsmanufacturer's specifications. Total RNA (5 pgflane; equal amounts tories, Wilmington, MA) injected intraperitoneally 3 days earlier of RNA in each lane were confirmed by equal intensity of ethidium with 3 a 10% sodium caseinate (DIFCO, Detroit, MI) in phos-bromide staining of ribosomal RNA bands and by hybridization of phate-buffered saline.'s.33 blots to @actin) was electrophoresed on 1 % agarose formaldehyde Purified human recombinant IL-6 (rIL-6) was a gift from Dr L. gels. Northern blots using Duralon-UV membranes (Stratagene, La Souza (Amgen, Inc, Thousand Oaks, CA) and used at a concentration Jolla, CA) were prepared and UV-cross-linked (Stratalinker; Stratof 100 n g / d . Granulocyte-macrophage colony-stimulating factor agene) before baking. Conditions for prehybridization, hybridization (GM-CSF) was used at a concentration of 100 U / d . P-Estradiol and washing, and stripping blots of probe to rehybridize were as (estrogen) was obtained from Sigma (St Louis, MO) and used at described p r e v i o u~l y .~~~~~ 2 pmol/L. a-Difluoromethylornithine (DFMO; a gift from Marion Merrill, Dow Research Laboratories, Cincinnati, OH) was used at 10 mmoVL, which was found to be optimal for ODC enzyme-inhibiting activity. Cycloheximide (Sigma) was used at 10 pg/mL.
Virus was generated from the plasmid forms of the retroviral vectors, pMV7 and pMV7-ODC (obtained from I.B. Weinstein, College of Physicians & Surgeons of Columbia University, N~~ York, ~y ) , 2 8 by transfection of the packaging cell line, PA3 17: supernatants obtained following transient transfection were used to infect M1 cells as previously described.34 Infected cells were selected for resistance to geneticin ((3418 sulfate; GIBCO) as previously de~cribed.~ Mlneo cell lines generated at this time were similar to parental M1 cells with regard to growth and differentiation characteristics.
Assays for differentiation-associated properties. Viable cell numbers were determined by trypan blue dye exclusion and counting in a hemocytometer. Fc and C3 receptors and cell adherence were determined by counting at least 300 cells on May-GrUnwaldGiemsa-stained cytospin smears and scoring the proportion of Continuous expression of ODC transcripts was observed up to 3 days following IL-6 stimulation of M 1 myc cells (Fig 1 A) . The level of ODC enzyme activity detected in Mlmyc cells following 3 days of IL-6 treatment was only slightly reduced relative to untreated control cells (Fig IC) . These results indicate that deregulated c-myc expression prevents significant ODC downregulation during M 1 myeloid differentiation.
ODC is a c-myc target gene activated by the chimeric mycer transgene. Recent reports have pointed out that ODC is a downstream target gene of the proto-oncogene, cmyc.24-26 That ODC continues to be expressed in IL-6-treated Mlmyc cells is consistent with ODC's being a crnyc target gene in differentiating M1 cells. To corroborate this, the M 1 mycer cell lines ectopically expressing the conditional mycer transgene were exploited. Mycer is a chimeric gene, in which the c-myc coding region is juxtaposed to the hormone-binding domain of the estrogen receptor gene, conferring hormone dependence on the function of the cmyc protein. Previously, we have shown that in the absence of estrogen, Mlmycer cells respond like M1 cells to IL-6; in the presence of estrogen, they respond like Mlmyc cells. Consistent with these observations, ODC expression was downregulated in Mlmycer cells treated with IL-6 in the absence of estrogen, and continued to be expressed at elevated levels in the presence of estrogen (Fig 2A) . To establish that ODC is a c-myc target gene, ODC mRNA expression in Mlmycer cells was analyzed 32 hours after IL-6 treatment, either with no additional treatment or with estrogen andor cycloheximide, an inhibitor of protein synthesis, for 3 additional hours. It was observed that ODC expression was induced in the presence of estrogen or estrogen plus cycloheximide (Fig 2B) . That ODC mRNA can be induced by the activated chimeric mycer protein in the absence of de novo protein synthesis demonstrates that ODC is a transcriptional target gene of c-myc in differentiating myeloid cells. Similar results were obtained using the estrogen antagonist, hydroxytamoxifen (OHT; data not shown).
OHT elicits binding of the estrogen receptor to DNA, but not activation of transcription, eliminating the possibility that ODC is induced by the portion of the estrogen receptor included in the mycer transgene. Consistent with ODC's being a target gene of c-my, activation of mycer led to an increase in ODC enzymatic activity in IL-6-treated Mlmycer cells (Fig 2C) .
Deregulated ODC is not suflcient to block myeloid differentiation. Altered or deregulated expression of c-myc has been shown to participate in cell transformation, to block terminal differentiation, and to promote apoptosis. ODC, a c-myc target gene, has been shown to be critical for cell and to be sufficient to induce accelerated apoptosis following IL-3 withdrawal in IL-3-dependent 32Dc13 myeloid cells." Taken together with the observations already described, ie, ODC was downregulated following induction of terminal myeloid differentiation and ODC continued to be expressed in Mlmyc myeloid cells that are blocked for terminal differentiation, it was reasonable to ask if deregulated ODC expression would be sufficient to block myeloid differentiation. To test this hypothesis, M1 cells expressing deregulated ODC were established and analyzed for growth arrest and differentiation following treatment with the differentiation inducer, IL-6. To establish M1 cell lines expressing deregulated ODC, M1 cells were infected with the retroviral expression vector, pMV7-ODC, and individual MI-ODC clones were selected in G41 8, as described earlier herein. All MI-ODC clones expressed long-terminal-repeat-derived ODC mRNAs (5 kb) in addition to endogenous mRNA (2.4 kb), as determined by Northern blot analysis of total RNA (Fig 3A) . In addition, clonally derived MI-ODC cell lines were found to have elevated levels of ODC enzyme activity relative to MI and Mlneo control cells (Fig 3B) .
To determine whether deregulated ODC activity was sufficient to block IL-6-induced differentiation, three M1-ODC clones were analyzed for response to IL-6. Following IL-6 treatment, all M 1 -0DC clones underwent terminal differentiation, similar to parental M1 and Mlneo cell lines. Differentiation was assessed by morphology ( Fig 3C and Table l) , adherence to the culture dish (Table l), growth arrest (Table  l) , and induction of Fc and C3 receptors, early differentiation markers ( Table l) . All MI-ODC clones expressed ODC enzyme activity following IL-6 treatment at a level at least as high as that in untreated M1 and Mlneo cells (Fig 3B) . Therefore, it can be concluded that enforced expression of ODC is not sufficient to block the myeloid differentiation program. Interestingly, although ODC is required for entry into the S phase of the cell cycle,'* continued expression of ODC did not prevent IL-6-induced growth arrest (Table l) to block myeloid differentiation, ODC expression may be necessary for the c-my-mediated differentiation block. This possibility was explored using DFMO, a well-characterized, specific, and irreversible inhibitor of ODC,39 to assess the effect of blocking ODC activity on MI and Mlmyc cells uninduced or induced to undergo terminal differentiation.
DFMO is an effective inhibitor of ODC enzyme activity in MI cells; it rapidly inhibited enzyme activity, with less than 10% of activity remaining after 30 minutes (data not shown). DFMO inhibited ODC enzyme activity in both parental MI and Mlmyc cells either treated or untreated with IL-6 (Fig 4A) . M1 cells treated concomitantly with IL-6 and DFMO appeared similar to MI cells treated only with IL-6 with regard to morphology, growth arrest, and induction of Fc and C3 receptors; therefore, DFMO had no deleterious effect on the IL-6-induced developmental program of M1 cells ( Fig 4B and Table 2 ). Since DFMO inhibited ODC enzyme activity of M 1 myc cells, it was possible to ascertain if ODC activity is required for the c-myc-mediated block in IL-6-induced terminal differentiation. DFMO had no effect on the block in terminal differentiation caused by deregulated expression of c-myc in Mlmyc cells, demonstrating that ODC expression is not necessary for the c-myc-mediated block in terminal differentiation of Mlmyc cells (Fig  4B and Table 2 ).
DISCUSSION
In this report, we have shown that ODC is downregulated following induction of myeloid differentiation, and that when differentiation is blocked by deregulated expression of c-myc ODC continues to be expressed. Using MI cells expressing the conditional mycer chimeric transgene, which requires estrogen for activation of c-my function, we demirreversible ODC inhibitor, DFMO, have shown that ODC onstrated that induction of ODC transcripts is dependent on is not required for the c-myc-mediated block in myeloid estrogen but not on de novo protein synthesis, consistent with differentiation. the notion that ODC is a c-my target gene. Establishment Although ODC has been shown to be a c-my target gene, of cell lines ectopically expressing ODC has shown that our data indicate that there are additional regulators of ODC deregulated expression of ODC is not sufficient to block gene expression. These data include the presence of ODC myeloid differentiation; in addition, experiments using the transcripts 24 hours after addition of IL-6 to MI cells at a M1 neo c IL-6 was used at 100 nglmL. Cells were seeded at a density of 0.15 X lo6. It has been shown that ODC is necessary for entry of cells into the S phase of the cell cycle.3x Our data demonstrate that ODC expression is not sufficient to allow myeloid cells, which have been stimulated to undergo terminal differentiation and its associated GO/GI arrest, to continue to cycle. cycle arrest is the observation that addition of putrescine, the compound that ODC catalyzes from ~rnithine,'~.~' at physiologic concentrations to the culture medium of M1 and Mlneo cells had no effect on the IL-6-induced differentiation program, including GO/G1 arrest (data not shown). These data suggest that other target genes of c-myc, either with or without ODC, are involved in the failure of Mlmyc cells to undergo GO/G1 arrest. That ODC participates in the failure of Mlmyc cells to undergo GO/G1 arrest following IL-6 treatment is suggested by the observation that the ODC inhibitor, DFMO, slows the growth of Mlmyc cells concomitantly treated with IL-6.
The reported effects of ectopic ODC expression on transformation and apoptosis involved elevated levels of ODC,28-3' in which the effect on apoptosis in factor-deprived 32D cells was due to ODC levels that were twofold to 12-fold higher than basal levels and the effect on transformation was in the presence of 20 to 100 times the endogenous ODC levels. Therefore, there may be insufficient ODC in M1-ODC cells to exert a change in response to myeloid differentiation inducers. However, it must be kept in mind that Mlmyc cells exhibit a block in IL-6-induced differentiation and fail to undergo GO/G1 arrest, yet ODC is expressed only at the basal level.
DFMO rapidly inhibits ODC activity, with less than 10% of activity remaining after 30 minutes. As reported, DFMO had no effect on the c-myc-mediated block in differentiation, which included the failure of Mlmyc cells to arrest in GO/Gl following treatment with IL-6. Intracellular pools of polyamines are unlikely to be present after treatment with DFMO for 3 days, since putrescine and spermidine levels are significantly reduced by 10 and 24 hours, re~pectively.~' It had also been reported that DFMO does not completely arrest cell growth, despite depletion of putrescine and spermidine.39 This is in agreement with our reported observations that DFMO does not cause growth arrest of M1 and Mlmyc cells, but causes a reduction in cell number of M1 and Mlmyc cells, with or without IL-6.
We have previously reported that blocking c-myc expression in both M1 and normal myeloid cells activates or accelerates, respectively, the myeloid differentiation program?' Blocking ODC expression by DFMO in proliferating M1 cells has no effect on these cells beyond slowing proliferation; no differentiation-associated characteristics were observed (Table 2) .
It is still an open question as to how c-myc exerts effects on differentiation. This study demonstrates that different or overlapping but not identical sets of c-myc target genes are responsible for the effect of c-myc on transformation, apoptosis, and differentiation. Functional analysis of known and unidentified c-myc target genes, separately and in combination, should generate further information toward deciphering how the proto-oncogene c-myc regulates terminal differentiation and its associated growth arrest, as well as transformation and apoptosis.
